Alfasigma S.p.A. Announces Expiration of Hart-Scott-Rodino Waiting Period
Alfasigma S.p.A. Tender Offer for Intercept Pharmaceuticals, Inc. Commences
It’s been an uphill battle for Intercept Pharmaceuticals in the three years since the FDA first nixed its attempt to bring Ocaliva to patients with nonalcoholic steatohepatitis (NASH)-related liver fibrosis.
POMEZIA, Italy, Oct. 20, 2022 /PRNewswire/ -- Alfasigma S.p.A. has completed the acquisition of SOFAR S.p.A., thus officially beginning the integrating process of the two companies.
Two years after Phase I data generated promise for bentracimab as the first drug to stop bleeding in patients that were prescribed AstraZeneca’s much-hyped stroke and heart attack drug Brilinta, PhaseBio has licensed it out to a European partner.
Alfasigma has signed an exclusive license agreement with PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS ), for the commercialization of bentracimab in 49 countries in Europe and other key markets.
Alfasigma enters into an exclusive license agreement with PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS ), for the commercialization of bentracimab in 49 countries across Europe as well as other markets keys.
Alfasigma USA, Inc. today announced a strategic deal with Indegene, Inc., a global life sciences and healthcare solutions provider, to co-promote its Irritable Bowel Syndrome with Constipation (IBS-C) drug, ZELNORM® (tegaserod), to prescribers across the United States. ZELNORM® was approved for reintroduction by the FDA for the treatment of adult women less than 65 years of age with IBS-C in March 2019. Alfasigma acquired the brand in July 2019 from Sloan Pharma S.a? r.l, a subsidiary of US WorldMeds Holdings, LLC.